Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
dimanche, octobre 25
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
EyePoint Inc
EYPT
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$0.4045
-0.0236
-5.51%
Dern. MÀJ: Oct 23, 7:54 PM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
EyePoint Financials
EyePoint (EYPT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Nasdaq Surges Over 1%; Fifth Third Bancorp Earnings Top Views
U.S. stocks mixed: Nasdaq +1.09%, S&P 500 +0.54%, Dow -0.12%. Tech led gains; utilities lagged. Oil fell, gold rose; Europe lower.
Avi Kapoor
PRO
EyePoint Pharmaceuticals Q2 EPS $(1.09) Misses $(0.95) Estimate, Sales $507.000K Beat $406.857K Estimate
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.95) by 14.74 percent. This is a 28.24 percent decrease over losses of $(0.85) per
Benzinga Newsdesk
Earnings Scheduled For May 6, 2026
Benzinga Insights
PRO
Eyepoint Reported $223M Of Cash And Investments As Of March 31, 2026, With Runway Into Q4 2027
Benzinga Newsdesk
PRO
EyePoint Pharmaceuticals Q1 EPS $(0.99) Misses $(0.80) Estimate, Sales $696.000K Beat $352.833K Estimate
Benzinga Newsdesk
Earnings Summary: EyePoint Q4
Benzinga Insights
